IMW 2019 | AML: hybridoma vaccines
David Avigan, MD, Harvard Medical School, Boston, MA, discusses the use of dendritic cell/tumour cell hybridoma vaccines for the treatment of acute myeloid leukemia (AML). Dr Avigan goes on to discuss the impressive efficacy data achieved with the use of this therapy and how hypomethylating agents may hold the key to increasing its potency further. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
Get great new content delivered to your inboxSign up